Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,140 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Flu Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

NCT05827978
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8,411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
103
States / cities
Anniston, Alabama • Athens, Alabama • Cullman, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

NCT06864143
View directory record Official record
Conditions
Influenza, SARS-CoV-2
Interventions
mRNA-1083 Composition 1 Dose A Lot A, mRNA-1083 Composition 1 Dose A Lot B, mRNA-1083 Composition 1 Dose B, mRNA-1083 Composition 1 Dose C, mRNA-1083 Composition 2 Dose A, mRNA-1083 Composition 2 Dose B, mRNA-1083 Composition 3 Dose A, mRNA-1083 Composition 3 Dose B, Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza Vaccine, Investigational COVID-19 Vaccine Lot A, Investigational COVID-19 Vaccine Lot B
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
17
States / cities
Scottsdale, Arizona • San Diego, California • Stockbridge, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

NCT00858468
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (2004-2005 Formulation)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
2 Months to 9 Months
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
8
States / cities
Little Rock, Arkansas • Marietta, Georgia • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 21, 2026, 4:26 AM EDT
Not listed No phase listed Observational

Platelet Immune Responses in Aging and Influenza and Sepsis (INVACS)

NCT03010410
View directory record Official record
Conditions
Sepsis, Influenza
Interventions
Not listed
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

NCT05868382
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1010, mRNA-1010.4, mRNA-1010.6
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
10
States / cities
Hollywood, Florida • Miami, Florida • Lenexa, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 21, 2026, 4:26 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

NCT05513391
View directory record Official record
Conditions
Influenza Immunization
Interventions
Recombinant influenza vaccine (RIV4), Quadrivalent influenza vaccine (IIV4)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
3 Years to 8 Years
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
18
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

NCT00391391
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine, Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
6 Months to 8 Years
Enrollment
520 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
19
States / cities
Harrisburg, Arkansas • Little Rock, Arkansas • Trumann, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional

Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma

NCT00307710
View directory record Official record
Conditions
Lymphoma
Interventions
Trivalent Baculovirus-expressed Influenza HA vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 4 Interventional

Randomized Influenza Vaccine Evaluation of Immune Response

NCT03598439
View directory record Official record
Conditions
Influenza
Interventions
Standard IIV4, Recombinant, Cell-culture
Biological
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study

NCT06503900
View directory record Official record
Conditions
Birth Outcomes, Safety, Adverse Event Following Immunization
Interventions
mRNA COVID-19 vaccine, IIV4 (quadrivalent inactivated influenza vaccine)
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies

NCT04531787
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Not applicable Interventional

Opting In vs Opting Out

NCT01233804
View directory record Official record
Conditions
Influenza Vaccination
Interventions
Opting Out
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Galveston, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Flu Shot Pre-visit Questionnaire

NCT05508698
View directory record Official record
Conditions
Influenza
Interventions
Precommitment Nudge, Salience
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
230,962 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

H1N1 Vaccine in Pregnant Women

NCT00963430
View directory record Official record
Conditions
Influenza
Interventions
Inactivated H1N1 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
St Louis, Missouri • Durham, North Carolina • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Not applicable Interventional

Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

NCT05663463
View directory record Official record
Conditions
Solid Organ Transplant
Interventions
Fluzone High-Dose - 2 doses, Fluzone High-Dose - 1 dose of HD
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 21, 2026, 4:26 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

NCT03376321
View directory record Official record
Conditions
Influenza A
Interventions
Pimodivir 600 mg, Placebo, SOC Treatment
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
13 Years to 85 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 21, 2026, 4:26 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Investigating the Effectiveness of a Seasonal Influenza Vaccination Promotion Campaign for Members of a Non-Profit, Community-Based Health Insurance Plan: 2018-2019

NCT03700281
View directory record Official record
Conditions
Influenza, Vaccination
Interventions
Messaging, Incentive
Behavioral
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years and older
Enrollment
22,584 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications

NCT06609460
View directory record Official record
Conditions
Influenza
Interventions
CD388 Injection, Placebo
Combination Product
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 63 Years
Enrollment
5,071 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
56
States / cities
Anniston, Alabama • Cullman, Alabama • Tempe, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Not listed Phase 2 Interventional

Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor

NCT00304720
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
Interventions
Tacrolimus and MMF
Drug
Lead sponsor
Colorado Blood Cancer Institute
Other
Eligibility
50 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 8, 2008 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Early Phase 1 Interventional

A Study of Acute Respiratory Infections in Global Outpatient Setting

NCT05148780
View directory record Official record
Conditions
Acute Respiratory Infection
Interventions
Nasal Swab Sample
Diagnostic Test
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Guntersville, Alabama • Mesa, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 21, 2026, 4:26 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Commercially Available Cannabis Products for Immune Support

NCT05944705
View directory record Official record
Conditions
Influenza, COVID-19, Common Cold
Interventions
Immune Support Supplement
Dietary Supplement
Lead sponsor
Center For Interventional Pain and Spine
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 1Phase 2 Interventional

T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza

NCT01728753
View directory record Official record
Conditions
Influenza
Interventions
Placebo, Favipiravir
Drug
Lead sponsor
MDVI, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunogenicity of ND1.1 by Delivery Directly to the Ileum

NCT01698060
View directory record Official record
Conditions
Avian Influenza
Interventions
ND1.1
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)

NCT04080245
View directory record Official record
Conditions
Influenza, Human
Interventions
Treatment Group Live Attenuated Flu Vaccine (LAIV)
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 21, 2026, 4:26 AM EDT